BRPI0410173A - composição farmacêutica para a prevenção e tratamento da viciação em nicotina em um mamìfero - Google Patents

composição farmacêutica para a prevenção e tratamento da viciação em nicotina em um mamìfero

Info

Publication number
BRPI0410173A
BRPI0410173A BRPI0410173-1A BRPI0410173A BRPI0410173A BR PI0410173 A BRPI0410173 A BR PI0410173A BR PI0410173 A BRPI0410173 A BR PI0410173A BR PI0410173 A BRPI0410173 A BR PI0410173A
Authority
BR
Brazil
Prior art keywords
addiction
treatment
mammal
prevention
pharmaceutical composition
Prior art date
Application number
BRPI0410173-1A
Other languages
English (en)
Inventor
Jotham Wadsworth Coe
Steven B Sands
Philip Andrew Iredale
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0410173A publication Critical patent/BRPI0410173A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA PARA A PREVENçãO E TRATAMENTO DA VICIAçãO EM NICOTINA EM UM MAMìFERO". A presente invenção refere-se a composições farmacêuticas para o tratamento da dependência ou viciação em nicotina, dependência ou viciação em tabaco, redução dos sintomas de abstinência de nicotina ou ajuda durante a cessação ou redução de consumo de tabaco ou abuso de substâncias ou outras dependências comportamentais. As composições farmacêuticas compreendem uma combinação terapeuticamente eficaz de um agonista parcial do receptor nicotínico e um antagonista do receptor CB1 e um veículo farmaceuticamente aceitável. O método de utilização destes compostos é também divulgado.
BRPI0410173-1A 2003-05-09 2004-05-05 composição farmacêutica para a prevenção e tratamento da viciação em nicotina em um mamìfero BRPI0410173A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46942903P 2003-05-09 2003-05-09
PCT/IB2004/001552 WO2004098580A2 (en) 2003-05-09 2004-05-05 A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal

Publications (1)

Publication Number Publication Date
BRPI0410173A true BRPI0410173A (pt) 2006-05-16

Family

ID=33435233

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410173-1A BRPI0410173A (pt) 2003-05-09 2004-05-05 composição farmacêutica para a prevenção e tratamento da viciação em nicotina em um mamìfero

Country Status (13)

Country Link
US (1) US20040224963A1 (pt)
EP (1) EP1624895A2 (pt)
JP (1) JP2006525992A (pt)
KR (1) KR20060009314A (pt)
CN (1) CN1784243A (pt)
AU (1) AU2004237153A1 (pt)
BR (1) BRPI0410173A (pt)
CA (1) CA2525225A1 (pt)
CO (1) CO5700713A2 (pt)
MX (1) MXPA05012088A (pt)
NO (1) NO20055767L (pt)
RU (1) RU2005131497A (pt)
WO (1) WO2004098580A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
KR20050088194A (ko) 2002-12-19 2005-09-02 머크 앤드 캄파니 인코포레이티드 치환된 아미드
ATE359075T1 (de) 2002-12-20 2007-05-15 Niconovum Ab Chemisch und physikalisch stabiles teilchenförmiges material enthaltend nikotin und microcrystalline cellulose
JP5694645B2 (ja) 2006-03-16 2015-04-01 ニコノヴァム エービーＮｉｃｏｎｏｖｕｍ Ａｂ 改善された嗅ぎたばこ組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
EP0937077B1 (en) * 1996-10-30 2006-05-17 Pfizer Inc. Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
IL136727A0 (en) * 1997-12-31 2001-06-14 Pfizer Prod Inc Aryl fused azapolycyclic compounds
WO1999055680A1 (en) * 1998-04-29 1999-11-04 Pfizer Products Inc. Aryl fused azapolycyclic compounds
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
TWI231757B (en) * 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity

Also Published As

Publication number Publication date
US20040224963A1 (en) 2004-11-11
KR20060009314A (ko) 2006-01-31
EP1624895A2 (en) 2006-02-15
WO2004098580A2 (en) 2004-11-18
CO5700713A2 (es) 2006-11-30
CA2525225A1 (en) 2004-11-18
AU2004237153A1 (en) 2004-11-18
CN1784243A (zh) 2006-06-07
NO20055767L (no) 2005-12-05
WO2004098580A3 (en) 2005-01-06
JP2006525992A (ja) 2006-11-16
RU2005131497A (ru) 2006-06-27
MXPA05012088A (es) 2006-02-22

Similar Documents

Publication Publication Date Title
BRPI0413693A (pt) composição farmacêutica para a prevenção e tratamento da viciação em um mamìfero
EA200970369A1 (ru) Композиции для снижения симптомов никотиновой абстиненции и/или отказа от употребления табака
WO2007088489A3 (en) Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
WO2004054511A3 (en) Analgesic combination comprising nalbuphine
WO2002094273A3 (en) Combination of an adenosine a2a-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways
AU3664401A (en) Platelet adp receptor inhibitors
NO20015931L (no) Farmasöytiske formuleringer og fremgangsmåter som omfatter intranasal morfin
WO2001091736A3 (en) Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
WO2002060392A3 (en) Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
YU2603A (sh) Nova kombinacija (5ht2) agonista i (5ht6) antagonista serotonina kao farmaceutska kombinacija
MXPA05011432A (es) Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina.
EP1078637A3 (en) Composition for the treatment and prevention of nicotine addiction containing a nicotine receptor agonist and an anti-depressant or anti-anxiety drug
EP1064966A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
BRPI0410173A (pt) composição farmacêutica para a prevenção e tratamento da viciação em nicotina em um mamìfero
TW200631956A (en) Azabenzoxazoles for the treatment of CNS disorders
WO2005062894A3 (en) Co-administration of dopamine-receptor binding compounds
WO2001045715A3 (en) Combinations of an adenosine a1 agonist with an opioid and their use in the treatment of pain
HUP0203032A2 (hu) Eplerenon gyorsan oldódó kristályos formája, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmények és alkalmazásuk
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
MXPA06002025A (es) Una composicion farmaceutica para la prevencion y tratamiento de adiccion de un mamifero.
MX2007010886A (es) Metodos y formulaciones de acarbosa para tratar constipacion cronica.
ATE277639T1 (de) Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten
BRPI0413608A (pt) composição farmacêutica compreendendo um ligante alfa2delta e um antagonista de receptor opióide para a prevenção e tratamento de dependência quìmica em um mamìfero

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.